INTELLECTUAL PROPERTY

Silence has built a strong and diverse intellectual property portfolio including proprietary siRNA delivery technologies, potent siRNA sequences and key siRNA structural features, as well as specific high-value disease targets. 

The company believes that this IP portfolio strategically provides a proprietary position in the RNAi therapeutics space.

Key assets include issued US and European patents and patent applications covering AtuRNAi and AtuPlex:

  1. Proprietary siRNA technology (AtuRNAi)
  2. Proprietary nucleic acid delivery technologies (AtuPlex, DACC and others)

 

Silence’s Intellectual Property Toolbox:

KEY IP ASSETS
  • Multiple Layers of Protection for Nucleic Acid Delivery including RNAi
  • Issued Patents on Specific siRNA Chemical Modification Patterns (AtuRNAi)
  • Pending and issued IP on siRNA Sequences
  • Exclusive License to Three Zamore Patent Families from University of Massachusetts
  • License to Fire & Mello Patent
  • Over 200 Issued and Pending Patent Applications Globally